These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 7785405)

  • 21. Sulfasalazine and new analogues in inflammatory bowel disease, with focus on Crohn's disease.
    van Hees PA
    Acta Gastroenterol Belg; 1987; 50(5):555-9. PubMed ID: 2902723
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.
    Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y
    Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease.
    Kreisel W; Wolf LM; Grotz W; Grieshaber M
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):461-8. PubMed ID: 8804875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Possible role in the treatment of inflammatory bowel diseases.
    Liu ZC; McClelland RA; Uetrecht JP
    Drug Metab Dispos; 1995 Feb; 23(2):246-50. PubMed ID: 7736919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of balsalazide therapy in the treatment of inflammatory bowel disease.
    Baker DE
    Rev Gastroenterol Disord; 2005; 5(3):135-41. PubMed ID: 16127348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Which 5-ASA?
    Mansfield JC
    Gut; 2003 May; 52(5):771. PubMed ID: 12692073
    [No Abstract]   [Full Text] [Related]  

  • 27. [Treatment and recurrence prevention ulcerative colitis].
    Schölmerich J
    Internist (Berl); 1995 Dec; 36(12):1124-32. PubMed ID: 8567217
    [No Abstract]   [Full Text] [Related]  

  • 28. Arachidonic acid metabolism and intracellular calcium concentration in inflammatory bowel disease.
    Schmidt C; Kosché E; Baumeister B; Vetter H
    Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):865-9. PubMed ID: 8574719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New derivates of salazopyrine in the treatment of chronic inflammatory bowel disease].
    Broide E; Scapa E; Abramowich D; Eshchar Y
    Harefuah; 1993 Feb; 124(4):223-5. PubMed ID: 8098698
    [No Abstract]   [Full Text] [Related]  

  • 30. Which 5-ASA?
    Travis SP
    Gut; 2002 Oct; 51(4):548-9. PubMed ID: 12235078
    [No Abstract]   [Full Text] [Related]  

  • 31. The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria.
    Edmond LM; Hopkins MJ; Magee EA; Cummings JH
    Inflamm Bowel Dis; 2003 Jan; 9(1):10-7. PubMed ID: 12656132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and preclinical development of a novel prodrug conjugate of mesalamine with eicosapentaenoic acid and caprylic acid for the treatment of inflammatory bowel diseases.
    Kandula M; Sunil Kumar KB; Palanichamy S; Rampal A
    Int Immunopharmacol; 2016 Nov; 40():443-451. PubMed ID: 27716592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
    Cohen HD; Das KM
    J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease.
    Nikolaus S; Fölscn U; Schreiber S
    Hepatogastroenterology; 2000; 47(31):71-82. PubMed ID: 10690587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
    MMW Fortschr Med; 2005 Apr; 147(17):58-9. PubMed ID: 15903063
    [No Abstract]   [Full Text] [Related]  

  • 36. [Side effects of 5-aminosalicylic acid].
    Marteau P; Cellier C
    Gastroenterol Clin Biol; 1997; 21(5):377-86. PubMed ID: 9208013
    [No Abstract]   [Full Text] [Related]  

  • 37. 5-aminosalicylates in inflammatory bowel disease--the more the merrier?
    Forbes A
    Eur J Gastroenterol Hepatol; 1995 Nov; 7(11):1017-9. PubMed ID: 8680898
    [No Abstract]   [Full Text] [Related]  

  • 38. Update on the aminosalicylates: a promise fulfilled.
    Peppercorn MA
    Gastroenterology; 1988 Dec; 95(6):1677-80. PubMed ID: 2903113
    [No Abstract]   [Full Text] [Related]  

  • 39. Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience.
    Tolia V; Massoud N; Klotz U
    J Pediatr Gastroenterol Nutr; 1989 Apr; 8(3):333-8. PubMed ID: 2565380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory bowel disease and male infertility: effects of sulfasalazine and 5-aminosalicylic acid on sperm-fertilizing capacity and reactive oxygen species generation.
    Wu FC; Aitken RJ; Ferguson A
    Fertil Steril; 1989 Nov; 52(5):842-5. PubMed ID: 2572460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.